此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Clinical Evaluation of Hearing Aid OTC Self-Assessment Methods for Adults With Perceived Mild-to-Moderate Hearing Loss

2026年7月30日 更新者:Rehear Audiology Company LTD

Clinical Evaluation of Two Rehear RH210 Self-Assessment Methods for Generating NAL-R-Based Prescribed Gain Compared With Conventional Audiometry in Adults With Perceived Mild-to-Moderate Hearing Loss

The goal of this clinical trial is to compare two methods of self assessment of hearing with conventional audiometry in an OTC Hearing Aid for adults with perceived mild to moderate hearing loss. The main questions it aims to answer are:

  1. To evaluate agreement between prescribed gain outputs generated from conventional audiometry and those generated from the self-assessment response method.
  2. Determine whether either self-assessment response method provides acceptable estimated audibility.
  3. Evaluate participant preference between the detection response method and the audibility-release response method.

Researchers will compare the two novel methods with conventional audiometry to determine levels of agreement.

Participants will self assess their hearing methods using two novel methods of hearing assessment as well as receive a conventional audiometric evaluation of hearing levels.

研究概览

详细说明

The purpose of this clinical investigation is to evaluate two RH210 hearing aid software self-assessment response methods used to generate NAL-R-based prescribed gain for adults with perceived mild-to-moderate hearing loss. The study will compare prescribed gain outputs derived from each RH210 self-assessment response method with prescribed gain outputs derived from conventional audiometry using the same NAL-R prescription approach. The study will also assess whether the resulting prescribed gain provides estimated audibility using Speech Intelligibility Index (SII) analysis, and will evaluate participant preference between the two self-assessment response methods. The RH210A is an air-conduction hearing aid designed for adults with perceived mild-to-moderate sensorineural hearing loss.

The two RH210 self-assessment response methods evaluated in this study are:

  1. Detection response method (Option 1): the participant presses a response control when they hear the tone or beep.
  2. Audibility-release response method (Option 2): the participant maintains a press while the tone or beep is audible and releases the response control when they no longer hear it.

The study is designed to:

  1. Evaluate agreement between NAL-R prescribed gain outputs generated from conventional audiometry and NAL-R prescribed gain outputs generated from each RH210 self-assessment response method.
  2. Compare the detection response method and audibility-release response method with respect to prescribed gain agreement by ear and frequency.
  3. Assess estimated audibility associated with the self-assessment-derived NAL-R prescriptions using Speech Intelligibility Index (SII) analysis.
  4. Determine whether either self-assessment response method provides acceptable estimated audibility, including in cases where prescribed gain does not exactly match the conventional-audiometry-derived NAL-R prescription.
  5. Evaluate participant preference between the detection response method and the audibility-release response method.
  6. Assess general agreement, completeness, invalid-test rate, usability and response consistency for each self-assessment response method.
  7. Support validation of the Rehear assessment-to-fitting pathway without positioning the RH210 self-assessment function as a diagnostic audiometer.

This study is not intended to establish Human Factors performance. However, observations arising during execution of the assessment workflow may identify opportunities to improve the user interface, workflow or user guidance before the final Human Factors validation study. These observations are exploratory development outputs and are not formal study endpoints.

研究类型

介入性

注册 (估计的)

24

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Sanna Hou, Master of Audiology
  • 电话号码:+61 2 9412 6872
  • 邮箱:sann.hou@nal.gov.au

学习地点

    • New South Wales
      • Macquarie Park、New South Wales、澳大利亚、2113

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age 18 years
  • Self-perceived mild-to-moderate hearing difficulties/ hearing loss
  • Competent smartphone use (able to complete self-fitting via the app)
  • Able and willing to provide informed consent
  • HHIA screening consistent with perceived hearing difficulty
  • Willingness and ability to attend two in-person research appointments
  • Ability to operate a SmartPhone

Exclusion Criteria:

  • Conductive or mixed hearing loss
  • Occluding cerumen
  • Otologic disease/ active ear pathology
  • Severe or profound hearing loss (PTA >S0dBHL) (WHO, 2021)
  • Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421)
  • Visible deformity of the ear (congenital or traumatic).
  • Fluid, pus, or blood coming from the ear (e.g., active drainage).
  • Sudden or rapidly progressive hearing loss within the recent past (often defined as within ~90 days).
  • Any acute or chronic dizziness or vertigo associated with hearing issues.
  • Pain or discomfort in or around the ear.
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears.
  • Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies)
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears

Exclusion Criteria:

-

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Conventional manual pure-tone audiometry
The comparator for this clinical investigation is conventional manual pure-tone audiometry performed in accordance with ANSI/ASA S3.21-2004 (R2023), Methods for Manual Pure-Tone Threshold Audiometry, followed by generation of a NAL-R-based prescribed gain output.
实验性的:Mode A
RH210 self-test method 1: detection response method, where the participant presses when they hear the tone or beep

The Investigational Medical Device (IMD) consists of the RH210 hearing aid software self-test function accessed through the Rehear smartphone application and used in combination with the RH210A compatible in-ear hardware platform.

For this clinical investigation, the RH210A hardware platform is used to present calibrated test sounds (pure tones) to the participant during the app-based self-test. The RH210A is not being evaluated as a diagnostic audiometer, and the study is not designed to evaluate the hearing aid's amplification performance.

The two RH210 self-test response methods evaluated in this study are:

  • Detection response method: the participant presses the response control when they hear the tone or beep (Mode A).
  • Audibility-release response method: the participant maintains the response control while the tone or beep is audible and releases the response control when they no longer hear the tone or beep (Mode B).
实验性的:Mode B
RH210 self-test method 2: audibility-release response method, where the participant releases the response control when they no longer hear the tone or beep

The Investigational Medical Device (IMD) consists of the RH210 hearing aid software self-test function accessed through the Rehear smartphone application and used in combination with the RH210A compatible in-ear hardware platform.

For this clinical investigation, the RH210A hardware platform is used to present calibrated test sounds (pure tones) to the participant during the app-based self-test. The RH210A is not being evaluated as a diagnostic audiometer, and the study is not designed to evaluate the hearing aid's amplification performance.

The two RH210 self-test response methods evaluated in this study are:

  • Detection response method: the participant presses the response control when they hear the tone or beep (Mode A).
  • Audibility-release response method: the participant maintains the response control while the tone or beep is audible and releases the response control when they no longer hear the tone or beep (Mode B).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Agreement of NAL-R prescribed gain outputs (dB) between the comparator conditions
大体时间:Day 1

The primary endpoint is the agreement of NAL-R prescribed gain outputs (dB), by ear (R/L) and frequency (Hz), between:

  • Conventional-audiometry-derived NAL-R prescribed gain (dB), and
  • RH210 self-test-derived NAL-R prescribed gain (dB), generated using each of the two RH210 response methods.

The frequency-specific analysis will include: 500 Hz; 1 kHz; 2 kHz; and 4 kHz.

The two RH210 response methods are:

  • Detection response method: participant presses when they hear the tone or beep (Mode A).
  • Audibility-release response method: participant releases the response control when they no longer hear the tone or beep Mode B).
Day 1

次要结果测量

结果测量
措施说明
大体时间
Number of Participants with Treatment-Related Adverse Events as classified by ISO14155:2026
大体时间:Day 1

The secondary safety objective is to assess the safety of participant exposure to the RH210 app-based self-test procedure when the RH210A in-ear hardware platform is used to present test sounds.

Safety will be assessed by the incidence, severity, seriousness and relationship to the investigational device or study procedure of:

  • adverse events;
  • adverse device effects;
  • anticipated adverse device effects;
  • discomfort associated with in-ear device use;
  • excessive loudness or sound intolerance;

No formal statistical hypothesis is proposed for safety. Safety outcomes will be summarized descriptively.

Day 1
Difference in Speech Intelligibility Index (SII) and SRT in quiet (CNC words) between the three conditions
大体时间:Day 1

The secondary objective is to evaluate whether RH210 self-test-derived NAL-R prescribed gain outputs (dB) provide estimated audibility comparable to the conventional-audiometry-derived NAL-R reference pathway.

The secondary endpoint is the difference in Speech Intelligibility Index / Audibility Index and SRT in quiet between:

(1) The conventional-audiometry-derived NAL-R prescribed gain condition (dB); and (2) Each RH210 self-test-derived NAL-R prescribed gain (dB) condition.

The analysis will be conducted under a pre-specified standard aided speech condition (SRT50% dB), for example adaptive speech in quiet SRT50, with the final method defined in the Statistical Analysis Plan

Day 1

其他结果措施

结果测量
措施说明
大体时间
Participant preference (A vs B questionnaire) will be assessed after completion of both self fit response methods.
大体时间:Day 1

The first exploratory objective is to evaluate participant preference between the two RH210 self-test response methods.

Participant preference will be assessed after completion of both RH210 response methods. The endpoint will include:

  • proportion of participants preferring the detection response method;
  • proportion preferring the audibility-release response method;
  • proportion reporting no preference;
  • reasons for preference, where collected. No formal hypothesis is proposed. Results will be summarized descriptively.
Day 1
Compare the practical performance of the two RH210 self-test response methods using NAL checklist.
大体时间:Day 1

Exploratory endpoints will include, for each response method:

  • completion rate;
  • invalid or unusable test rate;
  • missing frequency-specific data rate;
  • test duration;
  • participant-reported ease of use;
  • observed difficulty or need for clarification;
  • repeatability or response consistency, where repeat data are available.

No formal hypothesis is proposed. Results will be summarized descriptively.

Day 1

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Bettina Turnbull, Doctor of Audiology、National Acoustic Laboratories

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月15日

初级完成 (估计的)

2026年10月1日

研究完成 (估计的)

2026年10月1日

研究注册日期

首次提交

2026年7月26日

首先提交符合 QC 标准的

2026年7月26日

首次发布 (实际的)

2026年7月31日

研究记录更新

最后更新发布 (实际的)

2026年8月3日

上次提交的符合 QC 标准的更新

2026年7月30日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

The study is a commercial sponsor investigation of a product that is not yet cleared by regulatory agencies

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅